16 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Recent progress in the identification of adenosine monophosphate-activated protein kinase (AMPK) activators.

Pfizer
Synthesis and mechanism of hypoglycemic activity of benzothiazole derivatives.

Bar-Ilan University
Development of Novel Alkene Oxindole Derivatives As Orally Efficacious AMP-Activated Protein Kinase Activators.

Chinese Academy of Sciences
Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.

Cellzome
A quantitative analysis of kinase inhibitor selectivity.

Ambit Biosciences
Comprehensive analysis of kinase inhibitor selectivity.

Ambit Biosciences
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

Ambit Biosciences
Synthesis and SAR of 4-substituted-2-aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitors.

Pfizer
Substituted oxindol-3-ylidenes as AMP-activated protein kinase (AMPK) inhibitors.

University of Colorado Anschutz Medical Campus
Discovery of 4

TBA
Structure-based rational design of staurosporine-based fluorescent probe with broad-ranging kinase affinity for kinase panel application.

Takeda Pharmaceutical
Imidazolyl kinase inhibitors and uses thereof

Dana-Farber Cancer Institute
Pyridinecarboxamide derivatives, preparation method thereof and pharmaceutical uses thereof

Jiangsu Hengrui Medicine
Pyrazolo[3,4-c]pyridine compounds and methods of use

Genetech
Diazepinone derivatives

Novartis
Orally active 4-amino-5-diarylurea-furo[2,3-d]pyrimidine derivatives as anti-angiogenic agent inhibiting VEGFR2 and Tie-2.

Glaxosmithkline